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Lung infections associated with pneumonia or cystic fibrosis caused by Pseudomonas 
aeruginosa or other bacteria result in significant morbidity and mortality, in part owing to the 
development of multidrug resistance, also against last-resort antibiotics. Lytic 
bacteriophages — viruses that specifically kill bacteria — can reduce lung-associated 
infections, yet their clinical use is hindered by difficulties in delivering active phage to the 
deep lung. Here, we show that phage-loaded polymeric microparticles deposit throughout 
the lung via dry powder inhalation and that they deliver active phage. Phage-loaded 
microparticles effectively reduced P. aeruginosa infections and the associated inflammation 
in wild-type and cystic-fibrosis-transmembrane-conductance-regulator knockout mice, and 
rescued the mice from pneumonia-associated death. The polymeric microparticles might 
constitute a clinically translatable therapy for eradicating hospital-acquired lung infections 
and infections associated with cystic fibrosis.
Approximately 5.6 million cases of community-acquired pneumonia occur annually in the 
United States of America (USA), and it is the most common cause of death from infectious 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
*Correspondence to: andres.garcia@me.gatech.edu.
Author Contributions R.A., C.T.J., R.M.D., N.A.M. and A.J.G conceived and designed the experiments; R.A., C.T.J. and B.R.I. 
performed all the experiments. R.M.D. provided phage samples and provided advice on their use. B.R.I. and N.A.M. handled CF 
knockout mice breeding, testing and care. The manuscript was written by R.A., N.A.M. and A.J.G. All authors discussed the results 
and reviewed the manuscript.
Author Information Reprints and permissions information is available at www.nature.com/reprints. Correspondence and requests for 
materials should be addressed to A.J.G. (andres.garcia@me.gatech.edu).
Competing Interests
The authors declare no competing interests.
HHS Public Access
Author manuscript
Nat Biomed Eng. Author manuscript; available in PMC 2019 March 08.
Published in final edited form as:
Nat Biomed Eng. 2018 November ; 2(11): 841–849. doi:10.1038/s41551-018-0263-5.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
disease1. Another 200,000 cases of healthcare-associated pneumonia result in 36,000 annual 
deaths in the USA2. The lungs of cystic fibrosis (CF) patients (~29,000 annually3) also 
become colonized by pathogenic bacteria resulting in chronic infection and inflammation4. 
Pseudomonas aeruginosa is the main causative agent of morbidity and mortality in lung 
infections5,6. Antibiotic therapy is limited by dosing and multi-drug resistance4,5,7, and even 
last-resort antimicrobials8 are ineffective in eradicating infections9–12.
Phage are promising agents for the treatment of bacterial infections due to their ability to 
infect and lyse bacteria, replicate, and degrade biofilm matrix13–17. Because the mechanisms 
by which phage target bacteria are unrelated to the action of antibiotics, phage therapy is 
effective against multi-drug resistant bacteria18,19. The use of mixtures of phage reduces the 
development of resistance against phage therapy20. Phage are specific to one, or a few, 
closely related target bacterial species, and do not infect the commensal microflora of the 
patient21, which can be severely perturbed by antibiotics. In addition, phage have been 
shown to produce less endotoxin upon bacterial lysis compared to antibiotics such as β-
lactams22. Phage can be engineered to deliver biofilm-degrading enzymes, increase 
antibiotic efficacy, or provide alternative antibacterial strategies23–26. Recently, 
compassionate phage treatment of two patients with antibiotic-resistant bacteria in Europe 
and USA shows the translational potential, efficacy and safety of phage therapy27,28. Several 
studies have shown the potential of phage therapy to reduce lung bacterial infections29–38; a 
recent study showed that phage and the immune system act synergistically to clear 
pathogenic lung infections39. However, the use of nebulizers or intranasal administration in 
these studies limit phage stability, clinical translation, and patient compliance. To overcome 
these limitations, dry powder formulations of bacteriophage with or without excipients have 
also been tested40–45. However, rapid loss of phage activity due to exposure to harsh 
fabrication conditions, lack of a suitable carrier for deep lung delivery, and proof of efficacy 
in animal models are major challenges for clinical translation of phage therapy when used 
without suitable delivery vehicles. Here, we describe engineered phage-loaded 
microparticles (phage-MPs) for pulmonary administration via dry powder inhalation to 
deliver therapeutic doses of active phage to the site of infection and demonstrate significant 
reductions in bacterial counts and enhanced survival of the host. This therapeutic 
formulation is stable at room temperature and can be translated to conventional inhalers for 
ease of administration and increased patient compliance.
For pulmonary delivery, particles must have an aerodynamic diameter (daer) of ~1–5 µm for 
efficient deposition to the deep lung46. The daer is related to the physical diameter d and 
density ρ of the particle daer =   d ρ . For polymeric particles (ρ ≈ 1.0 g cm−3), particle 
diameter should be ~1–5 µm. However, at this size range, alveolar macrophages rapidly clear 
particles47, thereby reducing the therapeutic effect. To avoid clearance, particle diameter 
should exceed 5 µm, beyond the uptake capability of alveolar macrophages. This can be 
accomplished by using larger particles that are porous to reduce their density. Furthermore, 
large particles have lower aggregation compared to smaller particles and allow for improved 
aerosolization for dry powder formulations46. Such porous particles have been used for 
delivery of various therapeutics48–52, but their use for delivery of phage has not been 
reported.
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Results
Phage-MPs effectively kill bacteria.
We prepared hollow poly(lactic-co-glycolic acid) (PLGA) MPs via water-oil-water double 
emulsion (Fig. 1a-b). Porous particles were generated by including ammonium bicarbonate 
as an effervescent in the inner aqueous phase53. By tuning processing parameters, we 
generated highly porous MPs of appropriate size (d = 8.0 ± 4.5 µm) and density (~ 0.3 g cm
−3) to yield a daer of 2–5 µm (Fig. 1c-d, Supplementary Fig. 1).
Several lytic phage against P. aeruginosa (Supplementary Table 1) were amplified, purified 
by liquid chromatography, and loaded onto MPs by incubation in phage-containing solution. 
In this system, the phage is not encapsulated within the MPs but is deposited on the surface 
of the MPs after the MPs are synthesized. This approach minimizes any loss in phage 
activity from the solvents used for MP fabrication, and no loss of phage activity was 
observed upon loading. MPs were loaded with a defined mixture of 3–5 different phage to 
increase infectivity and bactericidal activity and reduce the probability for the development 
of resistance. Porous MPs provide large surface area for phage adsorption, and phage 
loading was 2.6 ± 0.2 plaque forming units (PFU) per particle or ~2.6 × 106 PFU mg−1 MPs. 
Endotoxin levels for the phage-MP formulation were 0.078 ± 0.003 EU/mg, two orders of 
magnitude below the 20 EU/device limit stipulated by FDA. As expected, these larger 
porous phage-MPs (8.0 µm diameter) exhibited reduced internalization by macrophages 
compared to non-porous, smaller (1 µm diameter) phage-particles (Supplementary Fig. 2). 
To test the bactericidal activity of phage-loaded MPs, phage-MPs or empty MPs were plated 
onto lawns of fluorescent P. aeruginosa PAO1-GFP and incubated for 16 h at 37oC. Efficient 
lysis of bacteria was observed around phage-MPs as demonstrated by zones devoid of 
fluorescence, whereas control MPs had no effect on PAO1-GFP levels (Fig. 1e-f). Notably, 
the killing zone for phage-MPs extended beyond the particle area, indicating that phage 
propagated radially outwards from the MPs, demonstrating that phage delivered from MPs 
can infect, replicate, propagate, and kill target bacteria beyond those in direct contact with 
the MPs. We next tested whether phage-MPs can infect and kill bacteria in synthetic sputum 
to model the viscous mucus in the lung. Synthetic sputum was prepared54 and growth curves 
in the presence and absence of phage-MPs were monitored. No growth was observed in 
presence of phage-MPs while bacteria rapidly grew in control conditions (Supplementary 
Fig. 3). This result demonstrates that phage-MPs can infect and effectively kill bacteria in 
viscous model sputum. A major challenge for treatment of lung-associated infections is the 
formation of biofilms by P. aeruginosa5,55. We tested the ability of phage-MPs to lyse 
bacterial biofilms. Treatment with phage-MPs resulted in effective killing of P. aeruginosa in 
biofilms (Fig. 2).
We prepared dry powder formulations of phage-MPs by lyophilizing phage-loaded MPs 
suspended in lactose. Dry powder formulations of phage-MPs were tested for 16 days and 
only showed a slight loss of titer when stored at room temperature (Supplementary Fig. 4). 
Such dry powder formulations can be easily administered to patients using inhalers, have a 
long shelf life, and increase patient compliance. We next performed studies to determine 
release kinetics of phage from dry powder MP formulations. An initial burst release of 
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approximately 10–15% of loaded phage was observed followed by very slow release 
(Supplementary Fig. 5), consistent with stable deposition of the phage on the particle 
surface and the slow degradation of the PLGA polymer used56. Attempts to characterize 
long-term release kinetics were not successful as this requires incubation of in aqueous 
buffer and there is loss of phage activity over time in aqueous environment at 37 °C.
Inhaled phage-MPs distribute throughout the murine lung.
For delivery to the mouse lung, lyophilized powder was mixed with inhalation-grade lactose 
and aerosolized using a mouse dry powder insufflator. We first evaluated the safety and 
clearance of MPs delivered via endotracheal intubation. Intravital imaging with near-infrared 
dye-labeled MPs showed that MPs were cleared from the lungs of healthy mice within 18 h 
(Supplementary Fig. 6). Histological sections at 1 and 7 days post-delivery demonstrated 
minimal leukocyte infiltration and normal lung tissue structure (Supplementary Fig. 7). No 
differences were observed in tissue histology between lungs receiving MP-lactose powder 
and control (no MPs) lactose powder.
We next evaluated the distribution of fluorescent MP-lactose dry powder after insufflation 
via endotracheal intubation. Organs were explanted immediately after delivery and imaged 
for total fluorescence. All fluorescence was localized to the lungs (Fig. 3a-b), and 
fluorescent MPs were found throughout lung tissue (Fig. 3c). These results demonstrate 
targeting of MPs to the lung as well as distribution throughout the lung via dry powder 
inhalation. To quantify phage delivery, we delivered phage-MPs or phage alone (no MPs) via 
insufflation. High phage titers (104-105 PFU/mg of tissue) were recovered from lungs 
treated with phage-MPs, whereas no phage were recovered from lungs receiving free phage 
(Supplementary Fig. 8a). These results demonstrate that delivery of phage using MPs 
significantly enhances the delivery of active phage to the lung. We also examined the deep 
lung distribution of phage-loaded porous and non-porous MPs. Phage were delivered as 
previously described and the deep lungs were harvested. Significantly higher deposition of 
phage in the deep lung was observed for delivery with porous MPs compared to non-porous 
MPs (Supplementary Fig. 8b).
An attractive attribute of phage compared to other antimicrobials is the ability to persist and 
replicate at infection sites until the pathogen is cleared. We established an acute model of 
lung infection using different PAO1-GFP doses and evaluated the persistence of bacteria at 
24 h post-inoculation in healthy mice (Supplementary Fig. 9). A dose of 5×106 CFU 
PAO1-GFP was selected for subsequent experiments. Phage-MPs were delivered to both 
control and PAO1-GFP-infected lungs, and 3 orders of magnitude higher phage counts were 
detected in PAO1-GFP-infected lungs compared to control (uninfected) lungs at 0 h 
(Supplementary Fig. 8) and 18 h post-delivery (Supplementary Fig. 10). This result 
demonstrates that phage delivered to the lung via MPs can infect and amplify in vivo only in 
the presence of target bacteria.
Phage-MPs treatment clears infection from mice lungs.
We tested the ability of phage-MPs to reduce acute bacterial lung infections in wild-type 
mice. Phage-MPs and controls were delivered via insufflation to PAO1-GFP-infected mice, 
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and lungs were assayed for bacterial and phage counts after 24 h (Fig. 4a-b). Delivery of 
phage-MPs reduced bacterial counts by an order of magnitude (p=0.0203) compared to 
bacteria + phage group whereas free phage (same dose as phage-MPs) delivery had no effect 
on bacterial counts (p>0.12) compared to animals treated with bacteria alone. Counts of 
phage active against P. aeruginosa were elevated for both free phage and phage-MPs. 
Importantly, treatment of infected mice with phage-MPs rescued 100% of subjects from 
pneumonia-associated death compared to only 13% survival for untreated mice over six days 
(Fig. 4c). These results demonstrate that phage-loaded MPs effectively reduce P. aeruginosa 
lung infections from wild-type mice and rescue mice from pneumonia-associated death.
We also examined the effects of phage-MPs on P. aeruginosa infection in the gut-corrected 
CF transmembrane conductance regulator (CFTR) knockout (CFKO) mouse57. This model 
mimics several aspects of the CF human condition, including increased pathogenesis from P. 
aeruginosa lung infections58,59. A dosing study with PAO1-GFP identified a suitable dose to 
obtain an acute infection (Supplementary Fig. 11). A dose of 2×106 CFU PAO1-GFP was 
used; this dose is lower than that needed for wild-type mice in the earlier experiment, 
suggesting that CFTR-KO mice have reduced capacity to clear bacteria from the lungs. 
PAO1-GFP infection and delivery of phage-MPs were performed as described earlier. 
Delivery of phage-MPs dramatically reduced bacterial counts in the lungs by three orders of 
magnitude, near the assay detection limit (Fig. 5a-b). In contrast to wild-type mice, 
treatment with phage alone also reduced the bacterial burden in the lung of CFTR-KO mice, 
but significant levels of bacteria were still present. This modest efficacy could be the result 
of higher phage:bacteria ratio as the bacteria dose delivered to CFTR-KO mice is lower than 
that for wild-type mice. Nevertheless, when comparing free phage to phage-MPs, use of 
phage-MPs resulted in ~1.5 orders of magnitude lower bacteria counts compared to free 
phage. Phage were detected in lung tissue for both phage-MPs and free phage. We assessed 
bacteria levels in the liver of these mice to determine whether the infection spread to other 
organs. Remarkably, no mice treated with phage-MPs showed any detectable bacteria in the 
liver (0 out of 7 mice), whereas >70% of untreated mice (5 out of 6 mice) or mice treated 
with free phage (5 out of 7 mice) had measurable levels of bacteria in the liver (Fig. 5c). 
Histological analyses revealed massive infiltration of host immune cells in untreated infected 
lungs (Fig. 5d). Infected mice treated with free phage displayed moderate levels of cell 
infiltration (Fig. 5e). Importantly, infected mice treated with phage-MPs had low levels of 
immune cell infiltration (Fig. 5f), indicating that this treatment reduces the bacterial load as 
well as infection-associated inflammation. Immunostaining analysis on lung sections 
confirmed these observations (Supplementary Fig. 12).
Phage-MPs kill clinical bacterial strains.
To evaluate the clinical potential of the phage-MPs formulation, we screened phage-MPs 
against clinical strains of bacteria isolated from hospital-associated lung infections and CF 
patients. The phage-MPs formulation was effective against all acute infection clinical strains 
and five out of six clinical strains from CF patients tested in vitro, including antibiotic-
resistant strains (CFBR 337 and CFBR 505 are tobramycin-resistant) (Supplementary 
Table 2). We then evaluated the in vivo efficacy of phage-MPs against PA103 (a historical 
strain derived from the sputum of a patient60) in mice. A dosing study with PA103 identified 
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a dose (1.6×105 CFU) suitable to obtain an acute infection in wild-type mice 
(Supplementary Fig. 13). To achieve high phage titers against PA103, our phage library 
was screened against PA103 and three different phage were chosen and loaded onto the MPs 
(Supplementary Table 3). PA103 infection and delivery of phage-MPs were performed as 
described earlier. Delivery of phage-MPs effectively reduced bacterial counts in the lungs 
showing efficacy against a patient-derived bacterial strain (Fig. 6a-b). To test whether direct 
deposition of phage onto MPs, instead of simple co-delivery of phage and MPs, is required 
for effective in vivo bacterial clearance, a physical mixture of phage and unloaded MPs with 
inhalation-grade lactose was evaluated. In contrast to effective bacteria reduction with 
phage-MPs, a physical mixture of phage and unloaded MPs did not reduce bacteria load in 
the lung (Fig. 6a), demonstrating that only phage that is directly deposited on the MPs kills 
bacteria in vivo. We also tested 10 bacterial colonies recovered from phage-MP treated mice 
for development of phage resistance against the stock phage mixture during the 18 h of 
incubation in the mouse lung. All of the recovered colonies were still sensitive to phage-
MPs.
Phage-MPs are effective against infection from multiple strains.
Another challenge for antimicrobial therapy against P. aeruginosa infection is the presence 
of distinct populations and their diversification in the patient lung 61,62. To test whether 
phage-MP treatment can be effective against infection consisting of multiple strains of 
bacteria, we infected mice with a mixture of PAO1-GFP (2.5×106 CFU) and PA103 (8×104 
CFU) strains. Phage listed in Supplementary Tables 1 and 3 were mixed and loaded on 
MPs. Treatment with phage-MPs effectively reduced total bacterial counts in the lungs, 
showing efficacy against infections comprised of simultaneous infection by two strains of P. 
aeruginosa (Fig. 6c). We also tested 10 bacterial colonies of each strain recovered from 
phage-MP-treated mice for development of phage resistance against the stock phage mixture 
and all recovered bacteria were still susceptible to phage-MP treatment.
Finally, to evaluate the efficacy of phage therapy after repeated administration, we delivered 
empty-MPs and phage-MPs in naïve mice. After 21 days, mice in both groups were infected 
with PA103 and phage-MPs treatment was performed. Pre-exposure with phage-MPs did not 
affect the efficacy of treatment when compared to no pre-exposure control group (Fig. 7). 
Furthermore, no antibody titers in blood (0/5 mice) were detected against phages at any time 
point tested (day 0, 21 and 22). This result indicates that pre-exposure to phage-MPs via dry 
powder delivery did not reduce its functional performance.
Discussion
We demonstrate that phage can be effectively delivered to lungs using polymeric MPs and 
MP-delivered phage retain its activity to kill host bacteria. Phage-loaded MPs significantly 
reduced P. aeruginosa infections and associated inflammation from healthy and CF mice and 
rescued mice from pneumonia-associated death. Importantly, phage-MPs were effective 
against clinically derived strains, including antibiotic-resistant strains, as well as lung 
infections caused by two strains of bacteria. The acute infection murine model used in our 
study lacks biofilm formation, mucus plugging, and genetic, phenotypic and spatial 
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diversification of bacterial strains 61,62. Nonetheless, we show that phage-MPs were 
effective against clinically derived strains from acute infections and CF patients and were 
able to kill bacteria growing in biofilms. Interestingly, when we delivered free phage to the 
healthy lung as a dry powder formulation and immediately assayed the lungs, we did not 
recover any active phage from the lung homogenate. This result is in contrast to prior studies 
29–34
, where free phage administration was shown to be effective against bacterial infections. 
This discrepancy could be due to differences in the mode of administration. All previous 
reports have used intra-nasal administration of phage in liquid, whereas we used dry powder 
formulation of free phage. Another reason for this discrepancy could be that the titers 
delivered for free phage in our experiment (~106 PFU/mg MPs) were significantly lower 
compared to previous reports (109-1010 PFU). For the acute lung infection model in healthy 
and CF mice examined in this study, phage-only treatment had modest efficacy in reducing 
bacterial burden even though active phage was recovered. In contrast, phage-MP treatment 
significantly reduced bacterial burden, rescued mice from pneumonia-associated death, and 
prevented bacterial colonization of the liver. We attribute this enhanced bactericidal efficacy 
for phage-MPs to improved delivery to the lung afforded by the engineered MPs. Indeed, 
direct deposition of phage onto the MPs was required for effective in vivo bactericidal 
activity as physical mixtures of phage and unloaded MPs had no effects.
Bacteria recovered from the lungs of infected mice treated with phage-MPs were tested for 
their susceptibility against phage-MPs, and all test samples were still susceptible to phage 
infection and lysis. Although this result suggests lack of phage resistance, more in-depth 
analysis in future studies is necessary. The present analysis focused on acute lung infection 
in healthy and CF murine models; future studies will test the efficacy of dry powder 
inhalation-based phage-MPs therapy in more challenging chronic infection models. Phage 
therapy (via intra-nasal route) has been recently been shown to be effective against P. 
aeruginosa chronic infections63. The mice used in our experiments are expected to have 
several commensal bacterial species 64,65. Although we did not investigate the effect of 
phage treatment on other resident species of bacteria in mice lungs, our treatment was able 
to reduce the counts of pathogenic bacteria from the whole lung microbiome. Even though 
phage are highly specific for their host species, it will be important for future studies to 
evaluate the effect of phage treatment on the entire lung microbiome, especially how 
targeting a single organism impacts the remaining organisms in that community. A concern 
with phage therapy is that immune responses to the phage could result in elevated, 
undesirable inflammation and immune reactions that could reduce phage activity. Indeed, 
intraperitoneal administration of phage resulted in high titer phage-specific antibodies in the 
blood 66. In the present study, we did not observe any adverse or elevated inflammation to 
phage-MP treatment nor the presence of phage-specific antibodies in the blood of treated 
mice. In addition, pre-exposure of phage-MPs did not result in reduction of its functional 
efficacy to subsequent bacterial challenge. These differences in host responses to phage and 
phage activity could be due to different routes of administration (IP vs. lung insufflation), 
phage dose delivered, and/or the use of MPs as phage delivery carriers. Further studies are 
needed to establish whether adverse immune responses, antibody production, and/or 
reduction in phage efficacy arise when phage-MPs are administered several times. 
Nevertheless, dry formulations of phage-MPs represent a promising alternative to antibiotic 
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regimens, which are severely limited by ineffective dosing and emergence of antibiotic 
resistance. The ability to deliver active phage using engineered biomaterials as dry powder 
formulations provides significant clinical benefits for lung infections, including longer drug 
stability, ease of administration with fewer side effects, and increased patient compliance.
Methods:
PLGA MPs:
MPs were prepared by double emulsion of water in oil in water. 200 mg PLGA (RG503H, 
Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 7 mL dichloromethane (DCM). 
Ammonium bicarbonate (ABC, Sigma-Aldrich) was used as an effervescent to create porous 
MPs in 1 mL of internal aqueous phase at 4% w v-1. The concentration of ABC can be 
varied to tune the porosity and density of MPs. The solution was homogenized at 3000 rpm 
for 2 min and then mixed with 50 mL of 1% poly(vinyl alcohol) (PVA) (Sigma-Aldrich) and 
homogenized for 2 min. The final emulsion was added to 100 mL 1% PVA and stirred to 
evaporate all DCM for 5 h. MPs were washed with deionized water 4 times to remove PVA 
and free polymer and lyophilized for 16 h. Fluorescent MPs were prepared by adding 1,1’-
dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate (DiI) or 1,1’-
dioctadecyl-3,3,3’,3’-tetramethylindotricarbocyanine iodide (DiR) dye (Thermo Scientific, 
Rockford, IL, USA) (5 mg dye per 200 mg PLGA) in DCM.
Particle size and density:
MPs size distribution was characterized using a Multisizer 3 Coulter counter. To determine 
density of MPs, 1.0 mg lyophilized MPs were suspended and counted in the Coulter counter. 
Total volume of MPs in 1.0 mg was calculated by using the average diameter obtained from 
the Coulter counter. Density was calculated by theoretical calculation based on mass = 
density*volume.
Scanning electron microscopy of MPs:
For scanning electron microscopy (SEM, LEO 1550), an MP suspension (5 μL of 1 mg mL
−1
 solution) was dispensed on a SEM stub, air dried for 2 h at room temperature, and sputter 
coated with 5 nm of gold to make the sample conductive. Imaging was done with a 5 KeV 
electron beam.
Fluorescent plaque imaging:
PLGA MPs were loaded with phage, washed, and various dilutions were plated with PAO1-
GFP on trypticase soy agar (TSA) plates. Plates were incubated for 18 h at 37oC and imaged 
on a Nikon-C2 laser scanning confocal microscope with a 10X objective. PAO1-GFP was 
excited with 405 nm laser and emitted light was collected through a 485/35 nm filter cube. 
Particles were excited with 561 nm laser and emitted light was collected through a 595/50 
nm filter cube.
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Phage amplification:
Phage (Supplementary Tables 1 and 3, described previously 67) were amplified in liquid 
culture of 25% trypticase soy broth (TSB) (Becton Dickinson, Sparks, MD, USA). Phage 
were added to an exponential phase, shaking culture of their respective bacterial host at 107–
108 CFU mL−1 and incubated at 37oC until lysis occurred (culture visibly cleared). The 
resulting lysate was clarified further by adding 2% (v v−1) chloroform, decanting 
centrifugation, and filtration of the supernatant (0.2 µm pore membrane).
Phage purification:
For phage purification, an anion-exchange chromatography column CIMs QA-8f mL Tube 
Column (BIA Separations, Ljubljana, Slovenia) was used 68. The column was attached to an 
AKTA™ FPLC system (GE Healthcare, Little Chalfont, UK) with P900 pump system and 
analyzed with UNICORN™ 5.01 software. Phage lysate was diluted 50% with Tris buffer 
(40 mM Tris-HCl, pH 7.5) and loaded onto the column. Phage were then washed with Tris 
buffer (20 mM Tris-HCl, pH7.5). For elution, a gradient was used by linearly mixing an 
increasing amount of 1.5 M NaCl, 20 mM Tris-HCl solution with 20 mM Tris-HCl buffer 
and collected using a fraction collector. Phage were then dialyzed with 0.1 M phosphate 
buffer supplemented with 2 mM MgSO4, passed through an endotoxin removal column and 
stored at 4oC.
Active phage counts:
Preparations were counted for active phage with plaque assays using the traditional top agar 
overlay method 69.
Phage loading on particles:
4 mg MPs were suspended in a solution of phage mixture (~1010-1011 phage mL−1) for 4 h 
with mild shaking. MPs were then washed 3 times with PBS. To determine phage loading 
levels on MPs, ΦPaer14 was loaded on the particles. 500 µL of phage-MP and 500 µL of 
chloroform were mixed for 20 min at room temperature to dissolve the PLGA. Free-phage 
standards were run in parallel to determine the effects of chloroform on phage stability. 
Samples were centrifuged at 500g for 5 minutes to separate the organic and aqueous phases. 
Phage titers were performed on the aqueous phase. Particles were enumerated using a 
hemocytometer and the number of phage per particles were calculated using the following 
formula ((PFU/mL) * adjustment) / (particles/mL), where the adjustment was determined by 
dividing PFU/mL of a phage standard by the PFU/mL of the same standard exposed to 
chloroform for 20 min as described above.
Dry powder preparation:
To prepare dry powder formulations, 4.0 mg of washed phage-MP were suspended in 100 
µL solution of lactose (40 mg mL−1) resulting in a 1:1 ratio of particle:lactose and 
lyophilized for 24 h. For free phage dry powder formulation, phage titers were adjusted to 
the amounts of phages loaded on the MPs, suspended in 100 µL solution of lactose (40 mg 
mL−1) resulting in a 1:1 ratio of particle:lactose and lyophilized for 24 h. For stability 
testing, the dry powder mixture was stored at room temperature. Phage activity in the 
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lyophilized powder was tested using the phage enumeration method described above on 
PA103. For in vivo work, lyophilized powder was mixed with 32 mg inhalation grade lactose 
(Respitose ML006, DFE Pharma) resulting in a 1:10 final ratio of particle:lactose. Powder 
was vortexed for 1 h at room temperature (VWR mini vortexer; speed 7).
Phage-MP endotoxin quantification:
Lyophylized phage-MPs (0.5 mg) were washed by centrifugation in 40 mL of endotoxin-free 
water as per the FDA Guidance for Industry Pyrogen and Endotoxins Testing (www.fda.gov/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm314718). Endotoxin was 
then quantified using a LAL chromogenic endotoxin quantification kit (Thermo Scientific, 
Rockford, IL, USA) per the manufacturer’s instructions.
Phage release from particles:
Lyophilized phage-MPs were suspended in PBS and total PFU were enumerated using the 
top agar overlay method. For phage release, phage-MPs were centrifuged at 500g for 5 min 
and the supernatant was assayed for PFU.
In vitro phage-MP phagocytosis:
RAW264.7 macrophages were cultured in DMEM supplemented with 4.5 g/L glucose and 
10% FBS in 24 well plates at 37 °C and 5.0% CO2 in a humidified incubator. Fluorescent 
DiI labeled particles were synthesized as described above. Smaller particles (0.94 ± 0.59 
µm) were generated by modifying the homogenization speed to 10,000 rpm. The PAO1 
phage mixture was loaded on the MPs. Following loading, MPs of different sizes were added 
to tissue culture media at a concentration of 0.25 mg/mL and incubated with cells for 2 h. 
Cells were washed 5 times with PBS to remove excess particles, fixed, and stained with 
DAPI and phalloidin-iFluor488 (abcam, Cambridge, MA). Samples were imaged using a 
Nikon-C2 laser scanning confocal microscope through a 10X objective. Three images of 
each well were acquired. Macrophage phagocytosis was evaluated in ImageJ by performing 
maximum intensity Z projections and thresholding the green (phalloidin) channel followed 
by particle tracking analysis (minimum size of 20 pixels) to identify the cell border. 
Fluorescent blue (DAPI) and red (MP) images were then overlaid and MPs falling inside cell 
borders containing a nucleus were counted as having been phagocytosed by cells. The total 
number of cells within an image field was quantified using the ComDet (v.0.3.6) plugin. The 
percent of phagocytic cells was computed by dividing the number of phagocytic cells in an 
image by the total number of cells in the image.
In vitro growth of bacteria in synthetic CF sputum:
Synthetic CF sputum was prepared as described previously54. 50 µL culture of PA103 was 
grown for 16 h in synthetic CF sputum and was used to inoculate 3 mL of the sputum 
medium in presence or absence of 0.1 mg of phage-MPs. Cultures were grown at 37oC and 
regular optical density measurements were taken to monitor the bacterial growth.
Agarwal et al. Page 10
Nat Biomed Eng. Author manuscript; available in PMC 2019 March 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In vitro activity of phage-MPs against bacterial biofilms:
To form biofilms, 5 µL culture of PA103 was grown for 16 h in 25% TSB and was used to 
inoculate 500 µL of 25% TSB in each well of a 48 well plate and allowed to grow for 24 h at 
37oC. Biofilms were carefully washed with PBS and incubated with 0.01 mg/mL of MPs or 
phage-MPs for 18 h at 37oC in 25% TSB. Biofilms were then washed and stained with 
LIVE/DEAD® BacLight™ (Thermo Scientific, Rockford, IL, USA) (3uL dye mixture per 
mL of bacterial medium) and imaged on a Nikon-C2 laser scanning confocal microscope 
with a 10X objective. SYTO9 (live cell stain) was excited with 488 nm laser and emitted 
light was collected through a 525/50 nm filter cube. Propidium iodide (to stain cells with 
compromised membrane that are considered dead or dying) was excited with 561 nm and 
emitted light was collected through a 595/50 nm filter cube. To prevent bleed through of 
fluorescence signal, each fluorophore was excited and emitted light collected in series. 
Image from each well was analyzed for mean pixel intensity in live and dead channel using 
ImageJ software (NIH, Bethesda, MD, USA). Ratio of mean intensity of live/dead was 
plotted.
In vitro activity of phage-MPs against clinical strains of bacteria:
To test activity of phages loaded on the MPs, a 5 µL drop of phage-MPs at 4 mg mL−1 was 
spotted onto a lawn of respective bacteria (Supplementary Table 2) and allowed to grow for 
16 h at 37oC. Formulation was defined as effective if the spot was visually cleared of any 
bacterial growth after 16 h incubation.
Bacterial inoculum preparation:
Colonies were re-suspended in sterile phosphate-buffered saline (PBS) and the optical 
density (OD) was measured at 600 nm. For each OD value, serial dilutions were plated on 
ampicillin-fortified (100 µg mL−1) LB agar plates for 24 h at 37°C with atmospheric CO2. 
Colonies were counted and plotted against their respective initial OD values. Bacterial 
challenges were performed with P. aeruginosa expressing green fluorescence protein (PAO1-
GFP) or the clinically derived bacteria strain PA103 (ATCC 29260). Bacteria were grown on 
ampicillin-fortified (100 µg mL−1) LB agar plates for 24 h at 37°C with atmospheric CO2. 
Colonies were removed from the plate with an inoculation loop and re-suspended in sterile 
PBS. OD measurements were taken of the solution and adjusted to achieve the required 
concentration based on previously determined OD growth curve for the respective bacteria.
Care and use of mice:
All experiments were conducted in accordance with Institutional Animal Care and Use 
Committee-approved protocols at the Georgia Institute of Technology and Emory University. 
All animals were housed in specific pathogen-free housing with 12 h:12 h light:dark cycles 
and had food and water ad libitum. The gut-corrected CF transmembrane conductance 
regulator (CFTR) knockout mouse Cftrtm1Unc Tg(FABPCFTR)-1Jaw/J57 (C57BL/6 and 
FVB/Nj background) was used in some experiments. These CFTR-KO mice are 
heterozygous for whole-body knockout of murine CFTR and have human CFTR expression 
regulated by expression of the fatty acid-binding protein promoter. As such, expression of 
human CFTR is limited to the small and large intestine with subsequent improved viability 
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and no dietary restrictions or special dietary supplementation compared to the whole-body 
knockout. C57BL/6 or wild-type littermates of CFTR-KO mice were utilized as wild-type 
mice. Both female and male mice were used (randomized) for experiments involving CFTR 
knockout and littermates. Only male mice were used for experiments involving C57BL/6 
mice. All animals were used within the age range of 8–14 weeks.
In vivo bacterial challenge:
Mice were placed under general anesthesia with an intraperitoneal injection of ketamine/
xylazine (100 mg kg−1 and 10 mg kg−1, respectively). Dry powder phage-MPs (1.0 mg) 
were delivered to lungs via a Dry Powder Insufflator™ model DP-4M (Penn-Century, 
Wyndmoor, PA, USA). Bacteria were inoculated using a Microsprayer® Syringe Assembly 
(model MSA-250-M, Penn-Century) by injecting 50 µL of appropriate OD of bacterial 
solution through an endotracheal tube. Successful lung delivery was confirmed by change in 
respiratory status of the animal. Mice were placed under a warming lamp and allowed to 
recover from general anesthesia. Eighteen to twenty-four hours following the intratracheal 
instillation of bacteria, mice were euthanized by intraperitoneal overdose of pentobarbital 
(150 mg kg−1, Euthasol) for organ collection. For assaying phage counts in tissues, organs 
were explanted, weighed and homogenized in sterile PBS. Homogenates were serially 
diluted and cultured on LB agar plates fortified with ampicillin (100 µg mL−1) to select for 
PAO1-GFP or PA103. Homogenate serial dilutions were also tittered for phages on the 
inoculating bacteria, either PAO1-GFP or PA103. Culture plates were incubated at 37°C and 
atmospheric CO2 and bacterial colonies or plaques were counted after 16 h incubation. For 
mixed infections, colony morphology was used to distinguish the different strains of 
bacteria. The detection limit of colonies was defined as 10 colonies in undiluted lung 
homogenate plates to prevent counting any lung tissue fragments as false positive.
Immune response against phages:
Mice were given no treatment or dry powder formulations of phage-MPs and empty-MPs. 
After 21 days, all mice were challenged with bacteria and were either treated with phage-
MPs or left untreated. Mice were euthanized after 18 hours and assayed for phage and 
bacteria as described above. For all time-points (day 0, 21 and 22), serum was collected via 
cheek bleed. To assay for the presence of antibodies, phage were incubated in a 96 well plate 
for 1 h and washed multiple times with 0.05% v/v Triton-X-100 in PBS. Samples were then 
incubated in 1% w/v casein blocker (Life Technologies). Samples were then treated with 
serum collected at each time-point (diluted 1:10 in PBS) for 1 h. Wells were then incubated 
with alkaline phosphatase (ALP)-conjugated anti-mouse antibody (1 µg/mL) (Jackson 
Immunoresearch, 715–055-151). Following several washes, samples were incubated with 5-
methyl umbelliferyl phosphate substrate (60 µg/mL) and fluorescence read at excitation/
emission of 360 nm/465 nm on a HTS 7000 Plus plate reader (Perkin Elmer, Akron, Ohio, 
USA).
Phage resistance:
Individual colonies recovered from phage-MPs treated mice were suspended in PBS and 
plated on TSA plates. A 10 µL drop of original phage mixture was spotted on soft agar 
seeded with the appropriate host strain and allowed to grow for 16 h at 37oC. Bacteria were 
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defined as susceptible to phage mixture if the spot was cleared of any bacterial growth after 
incubation for 16 h.
Live animal imaging:
Hair at the dorsum was removed and the animal was imaged using 750 nm excitation/800 
nm emission with an IVIS Spectrum CT system (Perkin Elmer, Waltham, MA, USA) or a 
Fluorescence Molecular Tomography imaging system (Perkin Elmer). Fluorescence 
intensity was analyzed using the manufacturer’s software.
Lung histology:
Lungs were harvested at necropsy and fixed in 10% neutral buffered formalin for 16 h, 
washed with PBS and dehydrated in 70% ethanol and embedded in paraffin. Sections (5 µm) 
were cut using a Microm 355H microtome and stained with hematoxylin and eosin. For 
immunohistochemistry, sections were treated with 0.05% trypsin for 10 min at 37°C, 
blocked with goat serum and stained with rabbit anti-P. aeruginosa antibody (Abcam 
ab68538, Cambridge, MA, USA). Slides were washed, blocked with goat serum and then 
stained with AlexaFluor 555-conjugated goat anti-rabbit IgG (Thermo Scientific, A21428) 
and DAPI. For lung cryosection images, fluorescent microparticles were delivered and mice 
were immediately euthanized. Lungs were harvested and mounted in OCT embedding 
compound and flash frozen in liquid nitrogen. 10–20 µm thick sections were cut using a 
cryostat (Leica CM3050 S). The slides were dried at room temperature for 30 mins, washed 
with PBS and stained with DAPI.
Statistical analysis:
All experiments were performed on independent biological replicates. Sample size for each 
experimental group and the statistical test used to determine significant differences among 
groups are reported in the appropriate figure legend. Non-parametric tests were used if the 
data did not meet the assumptions of t-tests or ANOVA. For in vitro experiments, sample 
size was not pre-determined, and all samples were included in the analysis. For animal 
experiments, sample size was determined based on power calculations to detect 20% 
differences among means using variances from previous/pilot experiments. All animals were 
used for analysis unless the mice died or had to be euthanized because of pre-defined 
euthanization criteria (significant weight loss, unresponsive to external stimuli) according to 
IACUC-approved protocols. The investigators were not blinded to outcome assessment.
Data Availability:
The authors declare that all data supporting the findings of this study are available within the 
paper and its supplementary information. The data in the figures are available from the 
corresponding author upon request.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Porous MPs deliver active phage and are effective against P. aeruginosa.
Scanning electron micrograph of (a) porous PLGA MPs and (b) non-porous PLGA MPs. 
Size distribution of (c) porous PLGA MPs and (d) non-porous PLGA MPs. Fluorescence 
microscopy images of green fluorescent protein expressing PAO1-GFP with (e) unloaded 
and (f) phage-loaded, fluorescent MPs (loaded with DiI stain).
Agarwal et al. Page 18
Nat Biomed Eng. Author manuscript; available in PMC 2019 March 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Phage-MPs are effective against P. aeruginosa biofilms.
Images of PA103 biofilms stained with SYTO 9 (green, live cells) and propidium iodide 
(red, dead cells) 24 h after treatment with (a-c) MPs only or (d-f) phage-MPs. g, 
Quantification of mean pixel intensity for live/dead bacteria using ImageJ. Measurements 
were taken from independent samples (n=4 for empty-MPs and n=5 for phage-MPs, mean ± 
SD, two-tailed t test with Welch’s correction).
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Figure 3. Dry powder formulations of porous MPs for lung delivery.
a, Fluorescence images of explanted organs immediately after MPs administration. b, 
Quantification of fluorescence signal from organs after fluorescent MPs administration (n=3 
mice, mean ± SD). Measurements were taken from distinct samples. c, Fluorescence 
imaging of lung cryosection after MP insufflation; nuclei stained with DAPI, MPs labeled 
magenta. Shown is a representative image from a total of nine images taken. Data were 
collected on male healthy (non-infected) C57BL/6 mice.
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Figure 4. Phage-loaded porous MPs reduce bacteria in the lungs of mice.
Antibacterial efficacy of free phage and phage-MPs was examined in a mouse model of 
acute lung infection with P. aeruginosa PAO1-GFP. After 24 h of treatment, (a) bacterial 
load (n=3 mice for MPs; n=11 mice for bacteria; n=6 mice for bacteria+MPs; n=9 mice for 
bacteria+phage; n=11 mice for bacteria+phage-MPs, mean ± SD) and (b) phage load (n=3 
mice for MPs; n=6 mice for bacteria; n=4 mice for bacteria+phage; n=6 mice for bacteria
+phage-MPs, mean ± SD) in lung homogenate were quantified. Data were pooled from two 
independent experiments. For (a), one-way Kruskal-Wallis non-parametric test was used to 
detect statistical differences followed by Dunn’s multiple comparison test with adjustment 
for multiple comparisons. * p = 0.0203. c, Percent survival of PAO1-GFP-inoculated mice 
that were untreated or treated with phage-MPs (n=8 mice/group). The Mantel-Cox test was 
used to detect differences between survival. Data were collected on male C57BL/6 mice.
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Figure 5. Phage-loaded porous MPs reduce bacteria in the lungs of CFTR knockout mice.
Antibacterial efficacy of free phage and phage-MPs was examined in a CFTR knockout 
mouse model of acute lung infection with P. aeruginosa (PAO1-GFP). After 18 h of 
treatment, (a) bacterial load (n=6 mice for bacteria and bacteria+phage-MPs; n=7 for 
bacteria+phage, mean ± SD) and (b) phage load (n=3 mice for bacteria and bacteria+phage-
MPs, 4 mice for bacteria+phage, mean ± SD) in lung homogenate were quantified. For (a-
b), data were pooled from two independent experiments. One-way ANOVA was used to 
detect statistical differences followed by Tukey’s multiple comparison test with adjustment 
for multiple comparisons. *** p < 0.0001 vs. bacteria control, $ $ $ p < 0.0001 vs. bacteria
+phage group. Data were collected on both male and female CFTR knockout mice. 
Measurements were taken from distinct samples. Images of histological sections of mouse 
lung stained with H&E at 18 h after treatment with (c) bacteria only, (d) bacteria + phage 
and (e) bacteria + phage-MPs. These are representative images from a total of five images 
taken for each group.
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Figure 6. Phage-MPs significantly reduce infection by a clinically derived strain of bacteria in 
wild-type mice.
Antibacterial efficacy of phage-MPs was examined in a mouse model of lung infection with 
the clinical strain of P. aeruginosa (PA103). After 18 h of treatment, (a) bacterial load (n=13 
mice for bacteria, 6 mice for bacteria+phage+MP, and 15 mice for bacteria+phage-MPs, 
mean ± SD) and (b) phage load (n=9 mice/group, mean ± SD) in lung homogenate were 
quantified. Data were pooled from two independent experiments. Data were collected on 
both male and female wild-type CFTR littermates. c, Antibacterial efficacy of phage-MPs 
was examined in a mouse model of lung infection with a mixture of P. aeruginosa strains 
(PAO1-GFP and PA103). After 18 h of treatment, bacterial load (n=4 mice/group, mean ± 
SD) in lung homogenate was quantified. Data were collected on male wild-type C57BL/6 
mice. For (a) one-way ANOVA was used to detect statistical differences followed by Holm-
Sidak’s multiple comparison test with adjustment for multiple comparisons. **p < 0.0001 
vs. bacteria control and p = 0.001 vs. bacteria + phage + MP groups. For (b,c), a two-tailed 
Welch’s t test was used to detect statistical differences. Measurements were taken from 
distinct samples.
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Figure 7. Pre-treatment with phage-MPs does not reduce functional efficacy of the treatment to 
clear bacteria from mouse lungs.
Antibacterial efficacy of phage-MPs was examined in a mouse model of lung infection after 
21 days of pre-treatment with phage-MPs or empty MPs with PA103. After 18 h of 
treatment, (a) bacterial load (n=4 mice/group, mean ± SD) and (b) phage load (n=4 mice/
group, mean ± SD) in lung homogenate were quantified. Data were collected on both male 
wild-type C57BL/6 mice. One-way ANOVA followed by Tukey’s multiple comparison tests 
were used to detect statistical differences.
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